AUTM on the Air

• Helping Universities Navigate Europe’s New Patent Landscape with Dr. Rose Hughes

  When cutting‑edge science collides with the realities of commercialization, tech transfer stops being paperwork and starts shaping the future of innovation. That intersection is exactly where European patent attorney and IPKat writer Rose Hughes has built her career, and today she’s here to break down what the latest headline decisions mean for anyone navigating patents on this side of the Atlantic. Dr. Hughes traces her journey from a PhD in infection‑immunity at University College London to training with Marks & Clerk, six years in‑house at AstraZeneca’s Cambridge R&D hub, and now a role at boutique firm Evolve, all while sharpening her public voice through IPKat’s mentored blogging model. In our conversation, Dr. Hughes unpacks the Enlarged Board’s looming opinion on reading claims in light of the description and why a Philip Morris case shows the hidden danger of boiler‑plate definitions. She explains G 2/21’s guidance on post‑field data using a polymorph dispute where vague promises of stability fell short, and she highlights how the UPC’s early Abbott v Sibio ruling suggests Europe’s new patent court is echoing EPO practice on functional language and added‑matter tests. We also dig into an Amgen peptide‑manufacturing opposition that weighs patent protection against trade secrets, and a recent Board decision where an AI‑driven cell‑analysis method collapsed for lack of technical character and data support.Dr. Hughes offers practical takeaways for university Tech‑Transfer offices from timing filings to fast‑moving science and preparing for AI tools that may automate drudge work but not strategic thinking. Along with candid advice for newcomers on following the science you love and using AI to focus on high‑value patent strategy.In This Episode:[05:16]  Dr. Hughes explains how launching the IPKat blog let her break down complex patent cases, deepen her own understanding, and build a go‑to resource for the European IP community.[08:22] We learn about some interesting cases that Dr Hughes has worked on recently. [09:33] The best IP is going to be grounded in the most exciting and innovative science.[10:06] We discuss some Enlarged Board of Appeals decisions and opinions about descriptions including the Philip Morris tobacco case.[13:05] Her advice is to be aware of boilerplate definitions. Also watch out for AI definitions.[15:15]  A deep dive into the Polymorph Patents ruling. [16:18] The Board of Appeal applying G2/21 said that you can use post-published data, but you can't just base it on sweeping statements in your application. Connect your features with how they are solving a problem.[17:43 ] Insights on the UPC’s Abbott  decision.The new court is likely to follow EPO precedent on added‑matter and claim interpretation.[20:27]  Dr. Hughes talks about an Amgen peptide manufacturing‑method case. [23:47]  A recent Board ruling on AI‑enabled cell‑therapy which uses AI to analyze the cell. (T 0660/22, Cell analysis/NIKON)[26:27]  There will be an increased use of AI tools and there will be challenges with how this is handled. [00:29:08] How tech transfer offices should approach European patent practice. There are significant differences between the two.[30:19]  The gap in antibody claim scope between the US and Europe is widening. [32:07] Predictions for trends and changes that could impact European patent practice and tech transfer in the next few years.[34:16] Advice for new patent attorneys and agents that are entering the field. Focus on the science that you are interested in. Gain as many different experiences as you can.[35:47] AI isn't going to take our jobs away; there will still be a role for patent attorneys. It will  automate the tedious processes.Resources: Dr. Rose Hughes - BloggerRose Hughes - LinkedInEvolve Pharmaceutical IPThe IPKat

  --------  

  38:05
• CRISPR Breakthroughs in Tuberculosis and Tech Transfer with Dr. Valwynne Faulkner

  This episode will illustrate how scientific research and tech commercialization can create a powerful impact. I'm excited to have Dr. Valwynne Faulkner on the show today. She is a postdoctoral researcher at the Francis Crick Institute and a LifeArc Knowledge Transfer Innovations Fellow. Her fascinating work spans cutting-edge molecular biology research and technology transfer.Val walked me through the work her team is doing with CRISPR to expose new ways of tackling tuberculosis, even the stubborn drug‑resistant strains. She also opened up about how the LifeArc fellowship is pulling her deeper into tech transfer, what she is learning about patents and partnerships, and why she thinks regulators need a seat at the table from day one.Whether you spend your days at the bench or in an office turning ideas into products, Val’s story shows how a curious mind and a collaborative spirit can move discoveries out of the lab and into the world.In This Episode:[01:12] We learn about Dr. Faulkner's current research at the Francis Crick Institute studying mycobacterium tuberculosis. [01:50] At the systems chemical biology lab they are developing CRISPR-based molecular tools that we can use to precisely control and silence genes.[02:13] This helps them understand the functional roles of genes in TB and response to antimicrobial drugs.[03:05] The hope is that the research will uncover new drug targets and help combat antimicrobial drug resistance.[03:46] Dr. Faulkner talks about the LifeArc Knowledge Transfer Innovations Fellowship. It helps teach scientists how to transition into careers within tech transfer. They get formal training and all aspects.[05:14] She learned about the program by chance. LifeArc was at the Francis Crick for a career event. [06:15] Her diverse experience across academia, industry and regulatory labs has given her a holistic perspective on research translation.[07:38] AUTM is a partner with the fellowship and gives them access to all of the online tools and learning centers. Along with excellent mentors and experienced professionals.[08:40] Insights gained from the AUTM 50th event. It's amazing how many stakeholders are involved.[09:37] Bridging the gap between scientific research and commercialization. The AUTM  Annual meeting has been crucial in facilitating knowledge exchange and networking.[10:49] A key challenge is navigating the complicated IP landscape. [11:57] Dr. Faulkner is excited about advancements in antimicrobial drug discovery.[13:04] Advice includes reaching out and asking questions and seeking things like fellowships. Be open to interdisciplinary collaborations.[13:53] The future of research innovation will be shaped by strong academic and commercial partnerships.Resources: Dr. Valwynne Faulkner - Francis Crick InstituteLifeArc

  --------  

  15:21
• How TTOs Can Lead the Way on Inclusion and Neurodiverse Innovation with Andy Williamson

  Building inclusive workplaces is not just good ethics, it is a major catalyst for innovation, creativity, and long term success. In this episode we take a closer look at how tech transfer offices can harness the untapped potential of neurodivergent talent and why doing so could transform not just individual careers but entire organizations.My guest is Andy Williamson, founder of Welcome Brain Consulting a UK-based consultancy pioneering neurodiversity inclusion in workplaces worldwide. Andy has spent over a decade helping organizations rethink how they hire, train, and support neurodivergent individuals from private companies to public institutions. His work includes developing the UK Industry Standard Neurodiversity in Events Checklist and advising on strategies that make workplaces more welcoming and effective for all kinds of thinkers. Andy shares how TTOs can create hiring practices that break down barriers, design workspaces that support focus and creativity, and foster cultures where every mind is valued. He explains why adapting communication styles, offering small workplace adjustments, and tracking the right metrics can make a huge difference, and why the business case for neuro inclusion is just as strong as the moral one. This is a thoughtful and practical conversation for anyone serious about building innovation ecosystems leaving no talent behind. In This Episode:[02:07] Andy shares why he founded Welcome Brain and some services they provide.[02:42] Andy talks about getting incredible results when tailoring learning for neurodivergent young people.[03:52] They help organizations support neurodiverse individuals within that organization.[04:25] They are currently working with the government with recruitment and hiring.[05:10] As many children are getting diagnosed, so are their parents. There are many neurodivergent adults.[07:37] Neurodiversity means thinking differently. This is what has made America great.[08:53] TTOs are hubs for translating research into real world impact. There are certain skills inherent in neurodivergent people that can be really helpful with systems thinking and seeing things that others miss.[10:23] Innovation is thinking differently. That's what neurodivergent people do. Incredible ideas and tremendous creativity.[11:25] Neurodiverse teams can be more productive. Andy talks about roles that neurodivergent people would excel at.[13:30] We talk about hiring and the recruitment process for neurodivergent people. The job description language, the screening process, and the interview process can filter out neurodivergent people.[15:59] Interview skills aren't the same as the skills required for the job.[16:24] Send interview questions in advance so people can prepare.[18:10] Being neuro inclusive will make you more money. Retention rates are also higher.[21:14] Office space and redesigning workspaces to increase focus. Things that can be done include creating acoustics around each zone.[23:41] Fostering psychological safety for neurodivergent individuals to share their needs and avoid stigma. Seeing other neurodivergent people creates a sense of safety.[27:28] Modeling inclusive behavior to shift team culture.[28:17] Managers need to be involved and communication is key[30:03] We learn about Welcome Brain's Certification Program. The initiatives need to be evaluated and measured.[33:12] We discuss the Neurodiversity In Events Checklist.[38:25] What TTOs should do to start creating neurodivergent inclusive environments. Resources:Welcome Brain Neurodiversity ConsultingAndy Williamson - Welcome Brain Neurodiversity ConsultingWelcome Brain - LinkedInAndy Williamson - LinkedInNeurodiversity In Events Checklist

  --------  

  42:52
• The Future of Tech Transfer: Navigating Chaotic Innovation with Nick Webb

  Innovation isn’t just evolving—it’s accelerating, fragmenting, and reshaping everything in its path. In this episode, we dive into what that means for the world of technology transfer, where traditional systems are being pushed to adapt or risk falling behind. If you’ve ever wondered how Tech Transfer Offices can keep up with the chaos of rapid innovation, this conversation will give you both clarity and direction.Our guest is Nick Webb, a bestselling author, futurist, and innovation strategist who has worked with some of the world’s top brands and holds more than 40 patents. He’s written influential books like The Innovation Mandate and What Customers Crave and leads consulting work that helps organizations future-proof their approach to innovation. In this episode, he brings that expertise to the challenges and opportunities facing universities and research institutions today.Nick talks about how TTOs can streamline operations, embrace smart automation, and build internal communication strategies that actually work. He shares how commercialization can be both profitable and socially impactful, how to better engage inventors in the process, and why building strong industry partnerships is no longer optional. It’s a fast-paced, eye-opening discussion for anyone working at the intersection of research and real-world impact.In This Episode:[01:44] His book, Chaotic Change was a look back at his 44 years in the innovation space. Things we're slow and small. When the internet came out everything was connected and digitized. Things became fast and big.[02:37] TTOs need to develop best practices and technologies to handle the amount and volume of a super complicated landscape.[03:02] With the AI shift and the next wave of chaos we'll see rapid adoption of new best practices, technologies, and systems.[03:41] One of the biggest inefficiencies is bureaucracy.[04:24] The importance of communicating to leaders and selling value as TTOs. The technology to accelerate is also important.[05:09] Commercialization is the ultimate force of impact. [06:06] Nick runs an AI lab and talks about the impact of AI Tech Transfer. We also need to keep our real intelligence in the process.[08:30] Nick talks about protecting IP for commercial success. Great strategic partners are a big help.[09:53] This would be a good time to reevaluate policies to see if it's a document that will increase technology licensing.[10:49] The importance of internal communication strategies for TTO offices.[11:34] Innovation Superstar Bootcamp has a master's and a startup program. It's about making the complexity of innovation management fun and understandable.[14:02] Striking the right balance between licensing startups and open Innovation models.[15:43] Collaborations and making the best partnerships work.[18:02] Practical steps to optimize operations without sacrificing impact. It starts with having a strategic plan.[19:26] Getting researchers interested in the commercialization process and thinking beyond their labs.[20:52] Lessons from Innovation Mandate that can be applied to TTOs to modernize their operations.[21:43] Taking a triage approach towards everything.[22:35] Don't waste time on technologies that don't stand a chance. Fast track methodologies. Sell your value proposition to get permission to move.[24:05] Monetizing non-traditional IP assets.[25:48] Trends to pay attention to. The experience ecosystem, the creation of AI artifacts, and business model innovations.[27:52] The Importance of being able to sell your value.[30:10] ESN an Enterprise Social Network.[31:05] Predictions for the future include automation, being hyper technical, and hyper human.Resources: Nick WebbWebb LogicNicholas Webb - LinkedInNicholas J. Webb - FacebookThe Innovation MandateWhat Customers CraveOther BooksLeaderLogic, LLCInnovation Superstar BootcampThe Healthcare Cure

  --------  

  32:16
• Turning Worms Into Medicine: Dr. Andrea Choe on Innovation, Impact, and Tech Transfer

  Could worms be the missing piece to treating allergies and autoimmune diseases? That’s the exciting idea that’s driving today’s guest, Dr. Andrea Choe, a scientist, doctor and biotech founder on a mission to change the way we think about human health.Dr. Andrea Choe is the CEO and co-founder of Holoclara, a biotech company that’s changing how we treat allergies and autoimmune disorders. While working on her PhD at Caltech, Andrea discovered a unique pheromone language shared by roundworms which led to insights in evolutionary biology and immunology. Today her research is the foundation of Holoclara’s mission to help millions suffering from allergies and autoimmune disorders.Today we’ll talk about how regions of the world where people live alongside worms have much lower rates of these conditions — and how Holoclara is working to tap into that evolutionary relationship in the form of safe, orally administered treatments. We’ll discuss the challenges of translating lab science into real world medicine, the regulatory hurdles of building a new class of drugs and why Andrea believes innovation should feel unconventional. And throughout it all she’s driven by one clear North Star: helping patients and families get relief.In This Episode:[01:52] Andrea shares how she made the roundworm discovery. Her thesis was on understanding the evolution of molecularcommunication between worms. She ended up discovering the shared unique pheromone language.[03:20] There were no allergies or autoimmune diseases before the 1900s.[04:29] Holoclara reflects the idea of completeness. This is Andrea's driving philosophy in life.[05:17] She believes that having a multidisciplinary approach to anything is always the best.[06:23] We learn about some of the many challenges that Andrea and her company has gone through.[09:43] They're trying to bring forward an entirely new class of medicine.[13:06] We learn about Andrea's experience with tech transfer and collaboration between Caltech and industry.[14:35] Approaching the regulatory path and listening to FDA guidance.[17:14] We learn about the team at Holoclara from R&D to clinical development.[18:25] The unconventional use of worms and innovation.[20:33] The treatment possibilities are far reaching. [21:06] Andrea shares how she's always motivated. She's really interested in figuring out how to change lives and get rid of chronic debilitating diseases. Resources: HoloclaraAndrea Choe - HoloclaraAndrea Choe - LinkedIn

  --------  

  23:40

More Technology podcasts

Trending Technology podcasts

About AUTM on the Air